Evidence map›Paper›PMID 36139425›Full record

ArticleCells2022

Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes.

Daniel Alonso-Miguel, Steven Fiering, Hugo Arias-Pulido

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Daniel Alonso-MiguelDepartment of Animal Medicine and Surgery, Veterinary Medicine School, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0003-4106-2278
Steven FieringDepartment of Microbiology and Immunology, and Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Health, Lebanon, NH 03756, USA.
Hugo Arias-PulidoDepartment of Microbiology and Immunology, and Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Health, Lebanon, NH 03756, USA.ORCID 0000-0003-4941-1110
Dartmouth–Hitchcock Medical Center · USUniversidad Complutense de Madrid · ES

Funding

Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.U01CA218292 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIERING, STEVEN, STEINMETZ, NICOLE FRANZISKA · 2017 to 2021
$3.0M
NCI NIH HHS R01 CA224605NCI NIH HHS U01 CA218292
6 · The paper itself

Abstract

Inflammatory breast cancer (IBC) is highly metastatic at the onset of the disease with no IBC-specific treatments, resulting in dismal patient survival. IBC treatment is a clear unmet clinical need. This commentary highlights findings from a recent seminal approach in which pembrolizumab, a checkpoint inhibitor against programmed cell death protein 1 (PD-1), was provided to a triple-negative IBC patient as a neoadjuvant immune therapy combined with anthracycline-taxane-based chemotherapy. We highlight the findings of the case report and offer a perspective on taking a proactive approach to deploy approved immune checkpoint inhibitors. On the basis of our recently published research study, we propose in situ vaccination with direct injection of immunostimulatory agents into the tumor as an option to improve outcomes safely, effectively, and economically for IBC patients.

Indexed as

Inflammatory Breast NeoplasmsAnthracyclinesHumansImmune Checkpoint InhibitorsImmunotherapyProgrammed Cell Death 1 ReceptorTaxoidsAnthracyclinesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorTaxoidscowpea mosaic virus nanoparticlesimmune checkpoint inhibitorsimmunomodulatorsinflammatory breast cancerin situ vaccinationneoadjuvant immunotherapypembrolizumabtoll-like receptorstriple-negative breast cancer

Identifiers

PMID36139425
PMCPMC9497132
OpenAlexW4295845756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.